Partnership-driven value in drug development: Compelling insights from new research

Partnering with a single vendor for comprehensive drug development, manufacturing, research, and clinical supply services can accelerate trial starts and substantially reduce development costs, according to new research by the Tufts Center for the Study of Drug Development. The study, which analyzed the impact of integrated service models on oncology drug programs, showed that this approach can significantly shorten development timelines across clinical phases while improving cost efficiency.

This approach, embodied by Thermo Fisher’s recently launched Accelerator™ Drug Development, tailors solutions across research and development, manufacturing, and clinical domains to meet the unique needs of each program. Providing cohesive and comprehensive support across the drug development journey by a single vendor helps sponsors streamline workflows, reduce risks, and maintain development momentum to reach the market faster.